Recent Investment Analysts’ Ratings Changes for DaVita (DVA)

DaVita (NYSE: DVA) has recently received a number of price target changes and ratings updates:

• 12/15/2025 – DaVita had its “buy” rating reaffirmed by analysts at UBS Group AG.
• 12/8/2025 – DaVita had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – DaVita had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/28/2025 – DaVita was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating.
• 11/25/2025 – DaVita had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – DaVita had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – DaVita had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/3/2025 – DaVita had its “hold” rating reaffirmed by analysts at Cowen Inc.
• 11/3/2025 – DaVita had its price target lowered by analysts at TD Cowen from $154.00 to $133.00. They now have a “hold” rating on the stock.
• 10/30/2025 – DaVita had its price target lowered by analysts at Barclays PLC from $149.00 to $143.00. They now have an “equal weight” rating on the stock.
• 10/30/2025 – DaVita was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating.

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.